Locoregional therapy and systemic cetuximab to treat colorectal liver XXXX .

@entity1 @entity5428 @entity2600 @entity984 @entity5 @entity648 @entity294 @entity1395 @entity887 @entity3929 @entity14 @entity3 @entity1349
AIM: To investigate efficacy and safety of second-line treatment with @entity2600 -loaded drug-eluting beads (DEBIRI) and cetuximab (DEBIRITUX) of unresectable colorectal liver @entity3 . METHODS: @entity1 with the following characteristics were included in the study: unresectable hepatic @entity3 from @entity14 ( @entity14 ), progression after first line chemotherapy (any type of chemotherapeutic drug and combination was allowed), second line treatment (mandatory), which included for each @entity1 (unregarding the @entity984 status) two cycles of DEBIRI (using 100-300  m beads loaded with @entity2600 at a total dose 200 mg) followed by 12 cycles of cetuximab that was administered weekly at a first dose of 400 mg/m(2) and then 250 mg/m(2); good performance status (0-2) and liver functionality ( @entity3929 aminotransferase and @entity5428 transferase not exceeding three times the upper limit of normal, total @entity648 not exceeding 2.5 mg/mL). Data were collected retrospectively and included: @entity5 response (evaluated monthly for 6 mo then every 3 mo), overall response rate (ORR), @entity984 status, type and intensity of adverse events (G according to the Common Terminology Criteria for Adverse Events v3.0, CTCAE), @entity1349 ( @entity1349 ) and progression free survival (PFS). RESULTS: Forty consecutive cases of CRC hepatic @entity3 were included in the study. Median duration of DEBIRITUX was 4.4 mo (range, 4.0-6.5). Sixteen @entity1 (40%) received the planned 2 cycles of DEBIRI and an average of 10 cetuximab cycles. ORR of the whole sample was 50%, in particular 4 @entity1 were complete responders (10%) and 16 (40%) partial responders. The most observed side effects (G2) were: @entity887 (30%), @entity294 (25%), skin rushes (38%) and @entity1395 (35%). The retrospective evaluation of @entity984 status (24 wild type, 16 mutated) showed that the group of @entity1 with wild type @entity984 had ORR significantly higher than mutant @entity984 . Median follow-up was 29 mo (8-48 range); median PFS was 9.8 mo and @entity1349 was 20.4 mo. Future randomized trials are required in this setting to establish a role for DEBIRITUX compared with systemic chemotherapy. CONCLUSION: DEBIRITUX seems to be efficacious after first line chemotherapy for the treatment of unresectable @entity14 .
